Home » Authors » Catherine Hollingsworth

Articles by Catherine Hollingsworth

Trevena Raises $35M in Series B To Fund Heart Failure Study

July 14, 2010

By Catherine Hollingsworth

iPierian Attracts New Investor Google in $22M Series B Round

July 9, 2010

By Catherine Hollingsworth

Bionovo to Raise $15M to Advance Plant-Based Pipeline

July 8, 2010

By Catherine Hollingsworth

Angion Advancing Phase II Drug for Renal Transplants

July 7, 2010

By Catherine Hollingsworth

Sunesis' $28.5M Stock Sale to Fund Voreloxin Phase III Trial

July 2, 2010

By Catherine Hollingsworth

Calistoga's $40M Series C Moves PI3K Inhibitor to Trial

July 1, 2010

By Catherine Hollingsworth

Obesity Data Show Drugs May Offer More Than Weight Loss

June 30, 2010

By Catherine Hollingsworth

Morphosys to Pay Xencor $13M Up Front for CLL Compound

June 29, 2010

By Catherine Hollingsworth

Metabolex Inks Diabetes Deal (Again); $375M from Sanofi

June 28, 2010

By Catherine Hollingsworth

Molecular Insight Stock Up on Phase II Cancer Data

June 25, 2010

By Catherine Hollingsworth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...